Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 62Squamous Cell Carcinoma of Head and Neck 46Breast Neoplasms 37Neoplasm Metastasis 34Parkinson Disease 4, Autosomal Dominant Lewy Body 33Carcinoma, Renal Cell 30Lung Neoplasms 29Colorectal Neoplasms 29Neoplasms 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 22Head and Neck Neoplasms 22Stomach Neoplasms 18Urinary Bladder Neoplasms 16Endometrial Neoplasms 15Carcinoma, Transitional Cell 15Pancreatic Neoplasms 13Prostatic Neoplasms 11Uterine Cervical Neoplasms 10Sarcoma 10Esophageal Neoplasms 10Small Cell Lung Carcinoma 9Recurrence 9Glioblastoma 8Fallopian Tube Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma 8Skin Neoplasms 7Oropharyngeal Neoplasms 7

Interventions

balstilimab 2tremelimumab 1spartalizumab 1pembrolizumab 1lenvatinib 1Standard of Care 1Pemetrexed 1Nivolumab 1Ipilimumab 1Carboplatin 1Axitinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Diabetes Mellitus, Insulin-Dependent, 12 × pembrolizumab × Clear all
NCT03530397 2026-05-19

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Active not recruiting
400 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡